PortalPublikationenAdoptive therapy with chimeric antigen receptor-modified T c...

Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition

Standard

Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. / Riddell, Stanley R; Sommermeyer, Daniel; Berger, Carolina; Liu, Lingfeng Steven; Balakrishnan, Ashwini; Salter, Alex; Hudecek, Michael; Maloney, David G; Turtle, Cameron J.

in: CANCER J, Jahrgang 20, Nr. 2, 29.03.2014, S. 141-4.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Riddell, SR, Sommermeyer, D, Berger, C, Liu, LS, Balakrishnan, A, Salter, A, Hudecek, M, Maloney, DG & Turtle, CJ 2014, 'Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition', CANCER J, Jg. 20, Nr. 2, S. 141-4. https://doi.org/10.1097/PPO.0000000000000036

APA

Riddell, S. R., Sommermeyer, D., Berger, C., Liu, L. S., Balakrishnan, A., Salter, A., Hudecek, M., Maloney, D. G., & Turtle, C. J. (2014). Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. CANCER J, 20(2), 141-4. https://doi.org/10.1097/PPO.0000000000000036

Vancouver

Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, Salter A et al. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. CANCER J. 2014 Mär 29;20(2):141-4. https://doi.org/10.1097/PPO.0000000000000036

Bibtex

@article{39bcd4166302462aa6091a4c6f0ba244,
title = "Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition",
abstract = "The ability to engineer T cells to recognize tumor cells through genetic modification with a synthetic chimeric antigen receptor has ushered in a new era in cancer immunotherapy. The most advanced clinical applications are in targeting CD19 on B-cell malignancies. The clinical trials of CD19 chimeric antigen receptor therapy have thus far not attempted to select defined subsets before transduction or imposed uniformity of the CD4 and CD8 cell composition of the cell products. This review will discuss the rationale for and challenges to using adoptive therapy with genetically modified T cells of defined subset and phenotypic composition. ",
keywords = "Antigens, CD19/immunology, B-Lymphocytes/immunology, CD8-Positive T-Lymphocytes/immunology, Humans, Immunotherapy, Adoptive, Lymphoma, B-Cell/immunology, Receptors, Antigen, T-Cell/immunology",
author = "Riddell, {Stanley R} and Daniel Sommermeyer and Carolina Berger and Liu, {Lingfeng Steven} and Ashwini Balakrishnan and Alex Salter and Michael Hudecek and Maloney, {David G} and Turtle, {Cameron J}",
year = "2014",
month = mar,
day = "29",
doi = "10.1097/PPO.0000000000000036",
language = "English",
volume = "20",
pages = "141--4",
journal = "CANCER J",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

RIS

TY - JOUR

T1 - Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition

AU - Riddell, Stanley R

AU - Sommermeyer, Daniel

AU - Berger, Carolina

AU - Liu, Lingfeng Steven

AU - Balakrishnan, Ashwini

AU - Salter, Alex

AU - Hudecek, Michael

AU - Maloney, David G

AU - Turtle, Cameron J

PY - 2014/3/29

Y1 - 2014/3/29

N2 - The ability to engineer T cells to recognize tumor cells through genetic modification with a synthetic chimeric antigen receptor has ushered in a new era in cancer immunotherapy. The most advanced clinical applications are in targeting CD19 on B-cell malignancies. The clinical trials of CD19 chimeric antigen receptor therapy have thus far not attempted to select defined subsets before transduction or imposed uniformity of the CD4 and CD8 cell composition of the cell products. This review will discuss the rationale for and challenges to using adoptive therapy with genetically modified T cells of defined subset and phenotypic composition.

AB - The ability to engineer T cells to recognize tumor cells through genetic modification with a synthetic chimeric antigen receptor has ushered in a new era in cancer immunotherapy. The most advanced clinical applications are in targeting CD19 on B-cell malignancies. The clinical trials of CD19 chimeric antigen receptor therapy have thus far not attempted to select defined subsets before transduction or imposed uniformity of the CD4 and CD8 cell composition of the cell products. This review will discuss the rationale for and challenges to using adoptive therapy with genetically modified T cells of defined subset and phenotypic composition.

KW - Antigens, CD19/immunology

KW - B-Lymphocytes/immunology

KW - CD8-Positive T-Lymphocytes/immunology

KW - Humans

KW - Immunotherapy, Adoptive

KW - Lymphoma, B-Cell/immunology

KW - Receptors, Antigen, T-Cell/immunology

U2 - 10.1097/PPO.0000000000000036

DO - 10.1097/PPO.0000000000000036

M3 - SCORING: Review article

C2 - 24667960

VL - 20

SP - 141

EP - 144

JO - CANCER J

JF - CANCER J

SN - 1528-9117

IS - 2

ER -